Jean-Pierre PELLETIER, MD, CSPQ, FRCP(C)Accredited member, Department of Pharmacology, Faculty of Medicine
Professor, Department of MedicineHead, Chair in Osteoarthritis, Université de Montréal
Head, Arthritis Centre, Université de Montréal
Head, Arthritis Division, Université de Montréal Hospital Centre (CHUM)
Director, Osteoarthritis Research Unit
University of Montreal Hospital Research Centre (CRCHUM)
1560 Sherbrooke Street East
Montreal, Quebec, H2L 4M1 CanadaTél. : 514 890-8000, poste 26666
Téléc. : 514 412-7582TrainingMedical degree, University of Montreal (1974)
Internal medicine FRCP(C) – CSPQ (1978)
Research fellow in rheumatology (1979-1981), Department of Medicine, University of Miami, Miami, Florida
Areas of ResearchPathophysiology and molecular mechanisms of human and experimental osteoarthritis
Pro-inflammatory cytokines and receptors
Proteolytic enzymes and inhibitors
Intracellular signaling pathways (i.e. MAP kinases) and transcription factors
Imaging (MRI) of osteoarthritis structural changes
Development of new therapeutics (DMOADs) for osteoarthritis
Techniques usedMolecular and cellular biology
Animal models of osteoarthritis
Laboratory personnelResearchers, research assistants, technicians, students: MSc, PhD, post-doctorate.
PublicationsWildi, L.M., Raynauld, J-P., Martel-Pelletier, J., Beaulieu, A., Bessette, L., Morin, F., Abram, F., Dorais, M., Pelletier, J-P. : Chondroitin sulphate reduces both cartilage volume loss and bone marrow lesions in knee OA patients starting as early as 6 months after initiation of therapy : a randomized, double-blind, placebo controlled pilot study using MRI. Ann. Rheum. Dis. 70 :982-989, 2011.
Pelletier, J-P., Troncy, É., Bertaim, T., Thibaud, D., Goulet, A-C., Abram, F., Caron, J., Boileau, C., d’Anjou, M-A., Moreau, M., Lussier, B., Martel-Pelletier, J : Treatment with tiludronic acid helps reduce the development of experimental OA lesions in dogs with ACL transection followed by reconstructive surgery : A 1-year study with quantitative MRI. J. Rheumatol. 38:118-128, 2011.
Raynauld, J-P., Martel-Pelletier, J., Beaulieu, A., Bessette, L., Morin, F., Choquette, D., Haraoui, B., Abram, F., Pelletier, J-P. : An open-label 12-month pilot study evaluating by magnetic resonance imaging the potential for a disease modifying effect of celecoxib compared to a modelized historical control cohort in the treatment of knee osteoarthritis. Semin. Arthritis Rheum. 40 :185-192, 2010.
Pelletier, J-P., Raynauld, J-P., Caron, J., Mineau, F., Abram, F., Dorais, M., Haraoui, B., Choquette, D., Martel-Pelletier, J. : Decrease in serum level of matrix metalloproteinases is predictive of the disease-modifying effect of osteoarthritis drugs assessed by quantitative MRI in patients with knee osteoarthritis. Ann. Rheum. Dis. 69 :2095-2101, 2010.
Raynauld, J-P., Martel-Pelletier, J., Bias, P., Laufer, S., Haraoui, B., Choquette, D., Beaulieau, A.D., Abram, F., Dorais, M., Vignon, E., Pelletier, J-P., and the Canadian Licofelone Study Group: Protective effects of licofelone, a 5-lipoxygenase and cyclooxygenase inhibitor, versus naproxen on cartilage loss in knee osteoarthritis: A first multi-centre clinical trial using quantitative MRI. Ann. Rheum. Dis. 68:938-947, 2009.
Prof. Bernard Combe is Professor of Rheumatology at Montpellier University, France, and Head of the Bone and Joint Department at Montpellier University Hospital.
He completed his medical education at Montpellier University and was subsequently awarded a research fellowship in clinical immunology at the University of Texas, San Antonio, USA.
Prof. Combe was elected member of the National Board of Universities (Rheumatology) from 1994–2000 and again from 2006, as well as being president from 2010–2013. He is an active member of numerous EULAR and ACR task forces. Prof. Combe is Editor-in-Chief of RMD Open (EULAR / BMJ journal) and of La Lettre du Rhumatologue. In addition, he is a member of the editorial boards of Annals of Rheumatic Diseases, Arthritis and Rheumatism and Joint Bone Spine. Prof. Combe has co-authored more than 315 articles published in international
peer-reviewed journals, and has been a coordinator or main investigator in 131 clinical trials.
Prof. JOHANNE MARTEL-PELLETIER, Ph.D. is Professor of Medicine in the Department of Medicine and Accredited Member of the Department of Pharmacology at the University of Montreal. In 1981, she co-founded with Professor Jean-Pierre Pelletier, the Osteoarthritis Research Unit at the University of Montreal Hospital Centre, which today is world renowned for its research in the field. In 2000, they initiated a University Chair in Osteoarthritis at the University of Montreal and have been appointed titular heads of this Chair.Her research interests lie in the mechanisms involved in the etiology of osteoarthritis, such as joint tissue catabolism and cartilage repair, the molecular and biochemical mechanisms involved during the osteoarthritis process of certain proteases, pro- and anti-inflammatory factors, and growth factors in humans and targeting new therapeutic strategies for the treatment of osteoarthritis. In addition, she is involved in developing systems using magnetic resonance imaging technology for the automatic quantification of structural tissue changes in the human knee and hip.She is an active member of several editorial boards and committees and is a highly respected reviewer for numerous rheumatology and connective tissue journals and governmental and private research funding agencies at national and international levels. She has authored more than 410 publications including journal articles, reviews and book chapters and over 730 abstracts, as well as being guest editor of several journals and editor of four books. In addition, she has been an invited guest speaker at numerous national and international meetings and conferences. She is recipient of several distinguished scientific awards honouring her excellence and outstanding achievements in osteoarthritis research.
Prof. Boulos Haraoui, MD FRCPC is an Associate Professor of Medicine at the Université de Montréal and head of the Clinical Research Unit in Rheumatology at the Centre hospitalier de l’Université de Montréal (CHUM) and the Institut de rhumatologie de Montréal.
Dr Haraoui received his medical degree from St. Joseph University in Beirut, Lebanon. Following his post graduate training in Internal Medicine and Rheumatology at the University of Montreal, he completed a research Fellowship at the Arthritis Branch of the National Institutes of Health in Bethesda, Maryland.
He is a founding member and vice-chairman of the Canadian Rheumatology Research Consortium (CRRC). He also chairs the Canadian Initiative in Outcomes in Rheumatology Care (CIORA), the research granting committee of the CRA
Doctor Haraoui is a Past-Chairman of the Scientific Committee of the Canadian Rheumatology Association.
He was an examiner for the Royal College of Physicians and Surgeons of Canada and a member of the Subspecialty Committee on Rheumatology of the RCPSC. He is also a past chairman of the Laurentian Conference of Rheumatology
Doctor Haraoui serves on several provincial, national and international educational and advisory committees, especially on issues pertaining to the diagnosis and management of rheumatoid arthritis.
Dr. Jordi Monfort Faure Graduated in Medicine at the Universitat Central de Barcelona, Specialty Registrar of Rheumatology, Parc de Salut Mar. Hospital del Mar Barcelona, Master in Biomedical Sciences, Université de Montréal, Profeciency University of McGill. Montreal, Master in hospital management International University of Catalonia, PhD, Universitat Autonòma de Barcelona 2010-2013
He is currently an Associated Professor of Rheumatology Universitat Autònoma de Barcelona
Dr. Flavia Cicuttini is a clinical rheumatologist and epidemiologist in the School of Public Health and Preventive Medicine with a long history of research in the area of musculoskeletal health. A major focus of her work has been on improving the methods for assessing joints using new methods such as magnetic resonance imaging. This has enabled a greater understanding of the mechanisms of early joint disease and has enabled new approaches to the prevention and treatment of arthritis.
Dr. Graeme Jones attended Sydney University graduating with first class honours in Medicine in 1985. He then did training in Internal Medicine and Rheumatology in Sydney and Newcastle. He became a fellow of the Royal Australasian College of Physicians in 1991. While at Newcastle he also did a Masters degree in Clinical Epidemiology. He then moved to the Garvan Institute in Sydney where he completed a doctorate in Osteoporosis Epidemiology in 1994. He is also a fellow of the Australian faculty of Public Health Medicine. Since 1995 he has been in Hobart, Tasmania where he combines clinical practice and research. He is currently Professor of Rheumatology and Epidemiology and Head of the Musculoskeletal Unit at the Menzies Research Institute as well as Head of the Department of Rheumatology at Royal Hobart Hospital. An NHMRC Practitioner Fellowship funds his position. He is also the current Medical Director of the Arthritis Foundation of Australia. He has received grants from competitive and non-competitive sources totalling over $16 million dollars and has published >250 articles primarily on the epidemiology of osteoporosis and osteoarthritis. In more recent years he has concentrated on both industry sponsored and investigator initiated clinical trials. He has received awards and given numerous oral presentations at the annual scientific meetings of the American Society for Bone and Mineral Research, the American College of Rheumatology, OARSI and EULAR. His current research interests are the development of peak bone mass and fracture aetiology in children, genetic and environmental risk factors for osteoarthritis, health promotion, the role of environmental factors such as diet and physical activity in osteoporosis and fractures in the elderly, clinical trials and meta-analysis.
Associate Professor Paul Bird (FRACP, PhD, Grad Dip MRI)
Paul Bird is a Rheumatologist in private practice and a Conjoint A/Professor at the University of New South Wales. In addition to his clinical and university responsibilities, he is the Director of Optimus Clinical Research, a clinical research center undertaking Phase 2, 3 and 4 trials of novel agents for the treatment of rheumatic diseases.
He maintains ongoing participation in research projects examining the application of Magnetic Resonance Imaging (MRI) in inflammatory arthritis and is co-chair of the OMERACT international MRI imaging group. He is a current member of GRAPPA (Group for Research and Assessment of Psoriasis and Psoriatic Arthritis).
Prof. Philip Conaghan MBBS PhD FRACP FRCP is Professor of Musculoskeletal Medicine at the University of Leeds and a Rheumatologist for the Leeds Teaching Hospitals NHS Trust. He is a Senior Investigator for the UK National Institute for Health Research (NIHR) and Deputy Director of the NIHR Leeds Musculoskeletal Biomedical Research Unit. His research spans translational studies through large clinical trials, with major interests in understanding pathogenesis and therapeutic response for common arthritides including osteoarthritis and rheumatoid arthritis. He is a senior executive member of the international outcomes group OMERACT. He was inaugural Chair of the EULAR Standing Committee on Musculoskeletal Imaging and is Past-President of the International Society for Musculoskeletal Imaging in Rheumatology. He is on a number of journal editorial boards, is co-editor of the most recent Oxford Textbook of Rheumatology and has authored over 400 publications as original research, reviews and book chapters.
Stephen Hall, Australia
Peter Nash, Australia
Kevin Pile, Australia